Genitourinary Cancers

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.

Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care supports long-term health.

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Hope helped me navigate my testicular cancer diagnosis at 20, shaping my resilience and guiding my journey as a survivor.

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies across kidney, bladder and prostate cancers.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

I often reflect on my emotional changes following a testicular cancer diagnosis and how I learned to manage them and grow.

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

A reflective Christmas morning run, following a cancer diagnosis, inspires profound gratitude for life and a renewed commitment to living a meaningful life.

For many years, I have trained my mind to have more discipline, especially after being diagnosed with testicular cancer in my 20s.

When a dear friend told me he has lung cancer, I opened up and shared my own perspective and experience as a survivor of testicular cancer.

Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients with renal cell carcinoma.

TULSA is a targeted prostate cancer treatment that uses ultrasound to destroy tumors while preserving healthy tissue.

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer.

After my surgery for testicular cancer, my good friend Joe helped me through my goal of training and running a marathon.

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a helpful tool.

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.